Rainier Group Investment Advisory LLC bought a new stake in shares of Colgate-Palmolive (NYSE:CL) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 1,494 shares of the company’s stock, valued at approximately $107,000.
Several other institutional investors and hedge funds have also made changes to their positions in CL. Stephens Inc. AR lifted its holdings in shares of Colgate-Palmolive by 12.2% in the 4th quarter. Stephens Inc. AR now owns 72,799 shares of the company’s stock worth $5,493,000 after acquiring an additional 7,924 shares during the last quarter. B.S. Pension Fund Trustee Ltd acting for the British Steel Pension Fund bought a new stake in shares of Colgate-Palmolive in the 4th quarter worth approximately $1,735,000. Crossmark Global Holdings Inc. lifted its holdings in shares of Colgate-Palmolive by 4.6% in the 4th quarter. Crossmark Global Holdings Inc. now owns 125,851 shares of the company’s stock worth $9,495,000 after acquiring an additional 5,524 shares during the last quarter. Cypress Wealth Services LLC bought a new stake in shares of Colgate-Palmolive in the 4th quarter worth approximately $222,000. Finally, Aries Wealth Management bought a new stake in Colgate-Palmolive during the 4th quarter valued at $1,154,000. Hedge funds and other institutional investors own 73.23% of the company’s stock.
A number of equities research analysts recently commented on the stock. Barclays set a $75.00 price target on shares of Colgate-Palmolive and gave the company a “hold” rating in a report on Thursday, March 15th. Sanford C. Bernstein reiterated a “market perform” rating and set a $72.00 price target on shares of Colgate-Palmolive in a report on Thursday, May 24th. Argus upgraded shares of Colgate-Palmolive from a “hold” rating to a “buy” rating in a report on Friday, May 25th. They noted that the move was a valuation call. Stifel Nicolaus reiterated a “hold” rating and set a $75.00 price target on shares of Colgate-Palmolive in a report on Wednesday, April 18th. Finally, Zacks Investment Research upgraded shares of Colgate-Palmolive from a “sell” rating to a “hold” rating in a report on Tuesday, April 17th. Four equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and three have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $76.08.
Colgate-Palmolive (NYSE:CL) last issued its quarterly earnings data on Friday, April 27th. The company reported $0.74 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.73 by $0.01. The business had revenue of $4 billion for the quarter, compared to the consensus estimate of $4.01 billion. Colgate-Palmolive had a net margin of 13.30% and a return on equity of 1,486.69%. The company’s quarterly revenue was up 6.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.67 EPS. analysts predict that Colgate-Palmolive will post 3.15 EPS for the current fiscal year.
In other news, Vice Chairman Franck J. Moison sold 80,000 shares of the company’s stock in a transaction dated Tuesday, May 15th. The shares were sold at an average price of $61.75, for a total value of $4,940,000.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Helene D. Gayle sold 7,000 shares of the company’s stock in a transaction dated Thursday, May 10th. The stock was sold at an average price of $62.23, for a total transaction of $435,610.00. Following the completion of the sale, the director now directly owns 35,395 shares in the company, valued at $2,202,630.85. The disclosure for this sale can be found here. Over the last three months, insiders have sold 142,079 shares of company stock worth $8,981,683. Insiders own 1.02% of the company’s stock.
Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. It operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The company offers oral care products, including toothpastes, toothbrushes, and mouthwashes, as well as pharmaceutical products for dentists and other oral health professionals; personal care products comprising bar and liquid hand soaps, shower gels, shampoos, conditioners, and deodorants and antiperspirants; and home care products, such as laundry and dishwashing detergents, fabric conditioners, household cleaners, and other related products.
Want to see what other hedge funds are holding CL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Colgate-Palmolive (NYSE:CL).
Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.